Skip to main content
Search

Edison Scientific

2 related articles

Subscribe to updates
  1. Incyte hands target assessment to Kosmos TA: one workday per target, and 83% of de-risking experiments match committee requests

    Incyte and Edison Scientific built Kosmos TA, a target-assessment version of the Kosmos AI scientist that continuously assembles literature, patents and other sources and brings safety, tractability and competitive intelligence into the package earlier. In a retrospective comparison scored against a rubric built from Incyte target-review meeting transcripts, Kosmos TA scored consistently higher than human-prepared assessments, with the largest gains outside the core biological rationale; on six targets with known committee decisions, 83% of its proposed de-risking experiments were a perfect or conceptual match to the experiments the committee actually requested.

  2. Edison Scientific

    Edison signs deployment deal with Pfizer: Kosmos agent to work inside oncology, internal medicine and immunology R&D data

    Edison Scientific announced an agreement to deploy the Edison AI Platform and its AI scientist Kosmos across Pfizer's biopharmaceutical R&D pipeline. Kosmos will access Pfizer's data in oncology, internal medicine, immunology and other areas to support Pfizer's scientists, inform critical R&D decisions and help accelerate discovery of potential new medicines. At the core is Kosmos's continuous learning, which combines public and Pfizer proprietary drug-development data into integrated world models, while Edison's forward-deployed scientists and engineers build Kosmos into specific workflows alongside Pfizer research teams.

You’re all caught up